Amgen News

ISIN
US0311621009
Symbol
AMGN
Berichte
Index
Dow Jones, NASDAQ-100, S&P 500
Sektor
Gesundheit
Industrie
Biotechnologie

News

The Motley Fool
3 Tage alt | Positiv
3 Healthcare Stocks With High Dividends
Looking for a healthcare stock that will pay you to own it? Here are three suggestions.
PRNewsWire
5 Tage alt | Neutral
LUMAKRAS® (SOTORASIB) RECEIVES APPROVAL IN JAPAN FOR PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER
THOUSAND OAKS, Calif., Jan. 20, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that LUMAKRAS® (sotorasib) has been approved in Japan for the treatment of KRAS G12C-mutated positive, unresectable, advanced and/or recurrent non-small cell lung cancer (NSCLC) that has progressed after systemic anticancer therapy.
GuruFocus
7 Tage alt | Positiv
3 Stocks Earning a Strong Return on Invested Capital
One way to identify high-quality companies is to consider their return on invested capital. The companies that can turn invested dollars into profits will likely see an increase in earnings per share, which can send share prices higher.
The Motley Fool
11 Tage alt | Positiv
1 Top Dividend Stock to Buy and Hold in 2022 and Beyond
This year should be better than last year for healthcare giant Amgen.
Seeking Alpha
13 Tage alt | Neutral
Amgen, Inc. (AMGN) CEO Robert Bradway Presents at 40th Annual J.P. Morgan Healthcare Conference (Transcript)
Amgen, Inc. (AMGN) CEO Robert Bradway Presents at 40th Annual J.P. Morgan Healthcare Conference (Transcript)
Seeking Alpha
14 Tage alt | Positiv
Amgen: Still A Good Pick For Bargain Hunters
Amgen reported solid results in the last quarter and the long-term growth story is still intact.
PRNewsWire
15 Tage alt | Neutral
EUROPEAN COMMISSION APPROVES LUMYKRAS® (SOTORASIB) FOR PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER
THOUSAND OAKS, Calif., Jan. 9, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) has granted conditional marketing authorization for LUMYKRAS® (sotorasib), a first-in-class KRASG12C inhibitor, for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy.
The Motley Fool
15 Tage alt | Positiv
My 3 Top Biotech Stock Picks for 2022
These stocks are poised for a strong year.
Mehr News anzeigen

aktien.guide Premium

Nichts mehr verpassen! Als Premium-Mitglied bekommst Du auf Wunsch alle Neuigkeiten zu ausgewählten Aktien direkt in Deine Mailbox.

Mehr erfahren